drugset / Trial / NCT04984512

The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder

NCT04984512 ↗

Phase 2/3 Recruiting 600 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of double-blinded treatment in phase 2 period and will be assessed by both efficacy and safety from 3 dose groups of Mitizodone Phosphate.The dose be found in phase 2 period will be evaluated on efficacy and safety when compared with placebo in phase 3 period with a duration of 8 weeks treatment.The target subjects are patients with MDD.

Timeline

Start
2021-12-14
Primary completion
2027-07
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitizodone Unknown 10 mg Oral
Subject Mitizodone Unknown 20 mg Oral
Subject Mitizodone Unknown 40 mg Oral